{"id":"https://genegraph.clinicalgenome.org/r/86eb1148-b905-474e-b30b-2aecf76e1499v1.0","type":"EvidenceStrengthAssertion","dc:description":"","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/86eb1148-b905-474e-b30b-2aecf76e1499","GCISnapshot":"https://genegraph.clinicalgenome.org/r/3d6848e7-6e9e-4545-9f97-69480face058","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/3d6848e7-6e9e-4545-9f97-69480face058_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2018-05-22T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/3d6848e7-6e9e-4545-9f97-69480face058_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2020-09-01T00:00:00Z","role":"Publisher"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3d6848e7-6e9e-4545-9f97-69480face058_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6a30991e-9c9a-4269-842e-caab8c40883f_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5db6f170-eed7-4db2-8152-175370f58b70","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20023066","rdfs:label":"Patient 3","ageType":"AgeAtReport","ageUnit":"Months","ageValue":33,"detectionMethod":"PCR and bidirectional sequencing of all exons and intron/exon boundaries of ETFDA, ETFA, and ETFB.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Suspected of having MADD following a positive newborn screen with multiple short, medium, and long chain acylcarnitine elevations. Plasma analysis confirmed screening abnormalities. Urine samples over 29 months showed only elevated ehtylmalonic acid. Elevation of 2-hydroxyglutaric acid was observed in some samples and was mild. Urinary glutarylcarnitine was elevated in most samples.","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/6a30991e-9c9a-4269-842e-caab8c40883f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20023066","allele":{"id":"https://genegraph.clinicalgenome.org/r/0f622436-f5e2-471e-b7c8-d1c668d2bcff","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000015.10:g.76225875A>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA393513831"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/41fe125d-5328-4bfa-be28-4bff1c4a9975_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Functional studies demonstrated that the p.Thr266Met variant protein show an altered flavin environment and reduced enzyme activity (Salazar et al. 1997).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5f615ead-62b6-47a1-9219-18dd240eef16","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1430199","rdfs:label":"1728","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Analyzed pre-alpha-ETF cDNA using GC-clamped denaturing gradient gel electrophoresis (DGGE), SSCP, direct DNA sequencing, and restriction endonuclease analysis.","phenotypeFreeText":"[9,10(N)-3H] palmitate and -myristate were 22% and 6% of control.","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/41fe125d-5328-4bfa-be28-4bff1c4a9975_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1430199","allele":{"id":"https://genegraph.clinicalgenome.org/r/46c5d203-bcdd-4164-8b3a-dd385315c023","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000126.3(ETFA):c.797C>T (p.Thr266Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/2594"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/89f364aa-d2b1-4d34-9090-e5c824f8aeb0_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The missense variant is the common pathogenic variant. The second mutation is an in-frame deletion.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/34d407f3-8b7e-4789-b600-4dd4dcd53955","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1430199","rdfs:label":"9001","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Analyzed pre-alpha-ETF cDNA using GC-clamped denaturing gradient gel electrophoresis (DGGE), SSCP, direct DNA sequencing, and restriction endonuclease analysis.","phenotypeFreeText":"[9,10(N)-3H] palmitate and -myristate were 8% and 22% of control.","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/89f364aa-d2b1-4d34-9090-e5c824f8aeb0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1430199","allele":[{"id":"https://genegraph.clinicalgenome.org/r/913d8fce-2e7a-4942-91b3-b72291b46b1e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000015.10:g.76274420_76274422del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA7673618"}},{"id":"https://genegraph.clinicalgenome.org/r/46c5d203-bcdd-4164-8b3a-dd385315c023"}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/76bda048-3f67-4efc-b147-8f80b4cfb20f_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The Thr266Met is the most frequent pathogenic mutation. Functional studies show an altered flavin environment and reduced enzyme activity (Salazar, 1997).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d27e79da-77a2-4866-bbf0-62804dd19b7a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12815589","rdfs:label":"Patient 6","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":2,"detectionMethod":"Total RNA isolated from fibroblasts, cDNA synthesized. ETFA was amplified in 5 overlapping fragments and PCR products were subjected to direct bidirectional cycle sequencing. ETFB and ETFDH were also analyzed. If 2 mutations were not detected, all exons and intron-exon boundaries were sequenced using genomic DNA.","phenotypes":["obo:HP_0001903","obo:HP_0001987","obo:HP_0002013","obo:HP_0008947","obo:HP_0002240","obo:HP_0001942","obo:HP_0001254","obo:HP_0000639","obo:HP_0001943"],"previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/76bda048-3f67-4efc-b147-8f80b4cfb20f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12815589","allele":[{"id":"https://genegraph.clinicalgenome.org/r/ffe6edac-8d1f-4f0e-9fda-e381baabc301","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"ETFA, IVS11DS, 1-BP DEL, +1G","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/2597"}},{"id":"https://genegraph.clinicalgenome.org/r/46c5d203-bcdd-4164-8b3a-dd385315c023"}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/4b445665-29e1-4c48-8566-3112589cb819_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/15efa402-a17c-4679-a461-ce1e7f1e6854","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16510302","rdfs:label":"Patient 12","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":2,"detectionMethod":"DNA extracted from patient fibroblasts. PCR and bidirectional sequencing of ETFA and ETFB.","phenotypeFreeText":"ETF activity 9% of control. Metabolic coma with hypoglycemia after 36 hour fast.","phenotypes":"obo:HP_0001943","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/4b445665-29e1-4c48-8566-3112589cb819_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16510302","allele":[{"id":"https://genegraph.clinicalgenome.org/r/7d43e959-e527-460c-a3be-2d5921b76cdb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000015.10:g.76231339_76231342del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658795161"}},{"id":"https://genegraph.clinicalgenome.org/r/e567376a-2a8b-45a9-9cf9-90074eb1cd7a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000015.10:g.76286439A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA7673746"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/be9a882a-6554-42e8-bd22-c65ebd61f8c1_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1cc6b367-ff81-49c8-9953-90c3b3557a64","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18289905","rdfs:label":"Patient 15","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":1,"detectionMethod":"PCR and sequencing of each exon and intron/exon boundaries of ETFA, ETFB, and ETFDH.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypes":"obo:HP_0006582","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/be9a882a-6554-42e8-bd22-c65ebd61f8c1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18289905","allele":[{"id":"https://genegraph.clinicalgenome.org/r/f666cb80-2eb0-4235-b1f5-218b995e1943","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000015.10:g.76274464C>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA393511053"}},{"id":"https://genegraph.clinicalgenome.org/r/d6e678d4-1a37-4a4b-afc6-a67ef8eead7f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000015.10:g.76286455del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658795155"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/4659a4c2-bede-445b-96b7-802fe49ea88a_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence. Note: the paper reports that the c.786A>G mutation results in p.Q262R, while the allele registry reports a synonymous change.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/908074a0-1e5a-45a3-a0bb-f05d913bae2a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20736750","rdfs:label":"Lee 2010 Proband","ageType":"AgeAtDeath","ageUnit":"Years","ageValue":14,"detectionMethod":"Mutation analysis performed on ETFA, ETFB, ETFDH for the patient. The corresponding exons of the family members were sequenced after mutations were identified in the patient.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Glucose 0.9 mmol/L, plasma creatine 179 umol/L, elevated ammonia 266 umol/L, elevated creatine kinase 15,340 U/L, c-reactive protein mildly elevated 10.3 mg/L, troponin I 0.48 ug/L. Postmortem exam showed marked and diffuse fat deposition in liver, kidneys and heart. Mass spec showed elevations of urinary glutaric, 2-hydroxyglutaric, ethylmalonic, isovalerylglycine and hexanoglycine. Elevated C4 to C16 acylcarnitines.","phenotypes":["obo:HP_0001942","obo:HP_0001943","obo:HP_0002098","obo:HP_0001695","obo:HP_0001289","obo:HP_0002013"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/4659a4c2-bede-445b-96b7-802fe49ea88a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20736750","allele":[{"id":"https://genegraph.clinicalgenome.org/r/176cc50d-5c45-4e32-b2a7-6d5ee87ff099","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000015.10:g.76286431C>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA7673745"}},{"id":"https://genegraph.clinicalgenome.org/r/c7c370e8-d488-45df-ba99-99f9774496be","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000015.10:g.76274442T>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA7673623"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/4612ac90-7ab1-4062-b419-339334cfc1c7_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/23aa6086-d82c-4785-916f-521b89674efa","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18289905","rdfs:label":"Patient 12","ageType":"AgeAtOnset","ageUnit":"Days","detectionMethod":"PCR and sequencing of each exon and intron/exon boundaries of ETFA, ETFB, and ETFDH.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypes":["obo:HP_0000113","obo:HP_0001943","obo:HP_0002094","obo:HP_0001987"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/4612ac90-7ab1-4062-b419-339334cfc1c7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18289905","allele":[{"id":"https://genegraph.clinicalgenome.org/r/768a9511-093a-4b33-88d7-1ba66f3c5b42","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000015.10:g.76311382G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA393519620"}},{"id":"https://genegraph.clinicalgenome.org/r/5ea0575b-b055-4d0a-af1f-560c9129296f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000015.10:g.76274429C>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA393510470"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/f52875c4-3edc-479b-a67f-30a924683e35_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ad3597d4-2aec-4b3f-bccc-81085a51fbbe","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1430199","rdfs:label":"1803","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Analyzed pre-alpha-ETF cDNA using GC-clamped denaturing gradient gel electrophoresis (DGGE), SSCP, direct DNA sequencing, and restriction endonuclease analysis.","phenotypeFreeText":"[9,10(N)-3H] palmitate and -myristate were 12% and 26% of control.","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/f52875c4-3edc-479b-a67f-30a924683e35_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1430199","allele":[{"id":"https://genegraph.clinicalgenome.org/r/46c5d203-bcdd-4164-8b3a-dd385315c023"},{"id":"https://genegraph.clinicalgenome.org/r/35f99df9-594b-43ea-a43b-18731d8c1edc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000126.3(ETFA):c.346G>A (p.Gly116Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/2595"}}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/0e5e0467-5e83-4739-8f43-5f2c1fd8a5c1_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d072b4ec-0e92-47c5-bab7-3c6bc515429d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16510302","rdfs:label":"Patient 4","ageType":"AgeAtDeath","ageUnit":"Days","ageValue":5,"detectionMethod":"DNA extracted from patient fibroblasts. PCR and bidirectional sequencing of ETFA and ETFB.","phenotypeFreeText":"ETF activity 3% of control","phenotypes":["obo:HP_0002344","obo:HP_0001942","obo:HP_0001943"],"previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/0e5e0467-5e83-4739-8f43-5f2c1fd8a5c1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16510302","allele":[{"id":"https://genegraph.clinicalgenome.org/r/b37b5e85-e50c-4fe7-9683-9d213d2cad36","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000015.10:g.76295725G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA7673866"}},{"id":"https://genegraph.clinicalgenome.org/r/26cfc785-8569-4efc-a926-43442bbe1883","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000015.10:g.76287866A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA7673765"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/9afa12ae-9240-4fde-894b-fcd0e33ae5da_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2e2c99a0-61e9-4172-98be-2ae32a89be19","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18289905","rdfs:label":"Patient 6","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":8,"detectionMethod":"PCR and sequencing of each exon and intron/exon boundaries of ETFA, ETFB, and ETFDH.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypes":["obo:HP_0001638","obo:HP_0011968","obo:HP_0003236"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/9afa12ae-9240-4fde-894b-fcd0e33ae5da_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18289905","allele":{"id":"https://genegraph.clinicalgenome.org/r/ac10fd99-0c08-46c7-bf82-eb6d5bed0119","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000015.10:g.76292499A>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA393517078"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/c950e6c8-5afe-47f7-9b6c-cc98be145429_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence. The missense variant has also been found in the homozygous state in another patient with neonatal onset (Indo, 1991). The second variant is an in-frame deletion.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/05384b49-9c9c-4201-a45d-b1f64d0bacf9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1430199","rdfs:label":"1430","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Analyzed pre-alpha-ETF cDNA using GC-clamped denaturing gradient gel electrophoresis (DGGE), SSCP, direct DNA sequencing, and restriction endonuclease analysis.","phenotypeFreeText":"[9,10(n)-3H] palmitate and -myristate were 7% and 13% of control.","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/c950e6c8-5afe-47f7-9b6c-cc98be145429_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1430199","allele":[{"id":"https://genegraph.clinicalgenome.org/r/92e8eb94-127b-463d-8d45-b500352e6dcb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000126.3(ETFA):c.470T>G (p.Val157Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/2593"}},{"id":"https://genegraph.clinicalgenome.org/r/6c4b4516-62de-4d89-a7ed-84d7d96e0d29","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000015.10:g.76286463_76286480del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658795156"}}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/3d6848e7-6e9e-4545-9f97-69480face058_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3d6848e7-6e9e-4545-9f97-69480face058_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b43a57f0-bd14-49eb-b5f3-f7945defd49b","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/703a1723-54a0-4eec-9be0-d8ddd6b15f80","type":"Finding","dc:description":"The zebrafish model showed large increases of acylcarnitines and glutaric acid associated with multiple abnormalities of organs including brain, liver, kidneys and heart. A large increase in triacylglycerides and decrease of phosphatidylserine species was also shown and has been observed in human tissue from a patient with MADD (Galloway, 1987). The defects in the model recapitulate many of the abnormalities seen in human patients with MADD.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23785301","rdfs:label":"ETFA Zebrafish","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/3d6848e7-6e9e-4545-9f97-69480face058_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0b248819-bf1c-4bca-b032-cf88780c332c","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c514d271-9351-4d8d-b13c-8b8225dd5061","type":"FunctionalAlteration","dc:description":"Assayed beta-oxidation flux in patient fibroblasts using beta-oxidation substrates (palmitate and myristate). Fibroblasts had low fatty acid oxidation activity (<3% of controls and 10% of control, respectively).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12815589","rdfs:label":"Reduced fatty acid oxidation"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/3d6848e7-6e9e-4545-9f97-69480face058_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ab428488-2a45-429f-ab9b-2fbe8f1765ed","type":"EvidenceLine","dc:description":"This is a well-known complex. Both subunits are required for electron transport and variants in either gene are known to cause the disease.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/57be3369-439e-4358-a7ce-2b0407a79495","type":"Finding","dc:description":"Crystal structure shows a complex that includes ETFA and ETFB.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15159392","rdfs:label":"ETF Complex","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4}],"evidenceStrength":"Definitive","sequence":434,"specifiedBy":"GeneValidityCriteria6","strengthScore":16,"subject":{"id":"https://genegraph.clinicalgenome.org/r/J3x2uK_9zEE","type":"GeneValidityProposition","disease":"obo:MONDO_0009282","gene":"hgnc:3481","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_3d6848e7-6e9e-4545-9f97-69480face058-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}